Literature DB >> 33585556

Baicalin Induces Apoptosis and Suppresses the Cell Cycle Progression of Lung Cancer Cells Through Downregulating Akt/mTOR Signaling Pathway.

Xinbing Sui1,2,3,4, Xuemeng Han2, Peng Chen2, Qibiao Wu4, Jiao Feng2, Ting Duan2, Xiaying Chen2, Ting Pan2, Lili Yan2, Ting Jin2, Yu Xiang2, Quan Gao2, Chengyong Wen2, Weirui Ma2, Wencheng Liu2, Ruonan Zhang2,3, Bi Chen2,3, Mingming Zhang2, Zuyi Yang2, Na Kong2, Tian Xie2,3, Xia Ding1.   

Abstract

Baicalin, as a natural active ingredient extracted and isolated from the traditional Chinese medicine Scutellaria baicalensis Georgi., has been potentially used in various areas for its antioxidative, antitumor, anti-inflammatory, and anti-proliferative activities. Although several studies have reported the antitumor effects of baicalin against various cancer types, its beneficial effects on lung cancer have not yet been elucidated. Therefore, the therapeutic effects and molecular mechanisms of baicalin on lung cancer cell lines H1299 and H1650 were investigated. Here, the results of its antitumor activity were shown. We found that Akt/mTOR pathway inhibition was the essential determinant in baicalin-induced cell cycle arrest. Furthermore, when the Akt Agonist SC79 or Akt plasmid transfection was performed, the antitumor effect of baicalin was significantly abrogated in both H1299 and H1650 cells. In conclusion, we found that baicalin exerted its antitumor activity mainly by inducing Akt-dependent cell cycle arrest and promoting apoptosis, which show great potential for developing a new drug for lung cancer treatment.
Copyright © 2021 Sui, Han, Chen, Wu, Feng, Duan, Chen, Pan, Yan, Jin, Xiang, Gao, Wen, Ma, Liu, Zhang, Chen, Zhang, Yang, Kong, Xie and Ding.

Entities:  

Keywords:  Akt; apoptosis; baicalin; cell cycle; lung cancer

Year:  2021        PMID: 33585556      PMCID: PMC7876332          DOI: 10.3389/fmolb.2020.602282

Source DB:  PubMed          Journal:  Front Mol Biosci        ISSN: 2296-889X


  18 in total

1.  Pan-Cancer Analysis Pinpoints Targets in PI3K Pathway.

Authors: 
Journal:  Cancer Discov       Date:  2017-06-15       Impact factor: 39.397

Review 2.  US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017.

Authors:  Mallorie H Fiero; Jessica K Roydhouse; Jonathon Vallejo; Bellinda L King-Kallimanis; Paul G Kluetz; Rajeshwari Sridhara
Journal:  Lancet Oncol       Date:  2019-09-30       Impact factor: 41.316

Review 3.  The dormant cancer cell life cycle.

Authors:  Tri Giang Phan; Peter I Croucher
Journal:  Nat Rev Cancer       Date:  2020-06-02       Impact factor: 60.716

4.  Baicalin prevents LPS-induced activation of TLR4/NF-κB p65 pathway and inflammation in mice via inhibiting the expression of CD14.

Authors:  Ya-Jun Fu; Bo Xu; Shao-Wei Huang; Xia Luo; Xiang-Liang Deng; Shuang Luo; Chang Liu; Qing Wang; Jin-Yan Chen; Lian Zhou
Journal:  Acta Pharmacol Sin       Date:  2020-05-26       Impact factor: 6.150

5.  Lung-targeting drug delivery system of baicalin-loaded nanoliposomes: development, biodistribution in rabbits, and pharmacodynamics in nude mice bearing orthotopic human lung cancer.

Authors:  Yumeng Wei; Jing Liang; Xiaoli Zheng; Chao Pi; Hao Liu; Hongru Yang; Yonggen Zou; Yun Ye; Ling Zhao
Journal:  Int J Nanomedicine       Date:  2016-12-29

6.  Baicalin combats glutamate excitotoxicity via protecting glutamine synthetase from ROS-induced 20S proteasomal degradation.

Authors:  Xianrui Song; Zixuan Gong; Kaili Liu; Junping Kou; Baolin Liu; Kang Liu
Journal:  Redox Biol       Date:  2020-05-16       Impact factor: 11.799

7.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Authors:  Matthew D Hellmann; Luis Paz-Ares; Reyes Bernabe Caro; Bogdan Zurawski; Sang-We Kim; Enric Carcereny Costa; Keunchil Park; Aurelia Alexandru; Lorena Lupinacci; Emmanuel de la Mora Jimenez; Hiroshi Sakai; Istvan Albert; Alain Vergnenegre; Solange Peters; Konstantinos Syrigos; Fabrice Barlesi; Martin Reck; Hossein Borghaei; Julie R Brahmer; Kenneth J O'Byrne; William J Geese; Prabhu Bhagavatheeswaran; Sridhar K Rabindran; Ravi S Kasinathan; Faith E Nathan; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

8.  Baicalin, a Chinese Herbal Medicine, Inhibits the Proliferation and Migration of Human Non-Small Cell Lung Carcinoma (NSCLC) Cells, A549 and H1299, by Activating the SIRT1/AMPK Signaling Pathway.

Authors:  Jiawen You; Jun Cheng; Bing Yu; Changhua Duan; Jinghua Peng
Journal:  Med Sci Monit       Date:  2018-04-10

9.  Baicalin ameliorates neuropathology in repeated cerebral ischemia-reperfusion injury model mice by remodeling the gut microbiota.

Authors:  Jianfeng Liu; Tianhua Zhang; Yingying Wang; Chengqing Si; Xudong Wang; Rui-Tao Wang; Zhonghua Lv
Journal:  Aging (Albany NY)       Date:  2020-02-21       Impact factor: 5.682

10.  Baicalin Regulates Proliferation, Apoptosis, Migration, and Invasion in Mesothelioma.

Authors:  Wen-Fei Xu; Feng Liu; Yi-Cong Ma; Zhi-Rong Qian; Long Shi; Hang Mu; Feng Ding; Xue-Qi Fu; Xu-Hui Li
Journal:  Med Sci Monit       Date:  2019-10-31
View more
  4 in total

1.  Baicalin improves the functions of granulosa cells and the ovary in aged mice through the mTOR signaling pathway.

Authors:  Huiying Fan; Jiahuan He; Yucheng Bai; Qina He; Tongwei Zhang; Junya Zhang; Guang Yang; Ziwen Xu; Jingyi Hu; Guidong Yao
Journal:  J Ovarian Res       Date:  2022-03-17       Impact factor: 4.234

2.  Recent insights into the biological functions of baicalin.

Authors:  Priscilla Nadalin; Jae Kwang Kim; Tae Won Kim; Sang Un Park
Journal:  EXCLI J       Date:  2022-08-01       Impact factor: 4.022

Review 3.  Chiral Flavonoids as Antitumor Agents.

Authors:  Cláudia Pinto; Honorina Cidade; Madalena Pinto; Maria Elizabeth Tiritan
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-05

4.  Baicalin suppresses lung cancer growth phenotypes via miR-340-5p/NET1 axis.

Authors:  Fucheng Zhao; Zhenxia Zhao; Yanru Han; Sujuan Li; Caili Liu; Kui Jia
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.